Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 146
Filter
1.
J Health Care Poor Underserved ; 35(2): 564-582, 2024.
Article in English | MEDLINE | ID: mdl-38828582

ABSTRACT

Background Black individuals with chronic musculoskeletal (MSK) pain tend to experience worse pain and opioid use-related outcomes, including other substance co-use, compared with non-Hispanic White individuals. Co-using cannabis with opioids could instigate a cascade of pain-related vulnerabilities and poor outcomes. Here, we test associations between cannabis/opioid co-use and pain-related outcomes among Black individuals with chronic MSK pain. Methods Black adults with chronic MSK pain who use opioids (N=401; 51.62% female, Mage=35.90, SD=11.03) completed online measures of pain intensity/interference, emotional distress, opioid dependence, and risky use of other substances. Results Compared with opioid use alone, opioid and cannabis co-use was associated with elevated anxiety and depression symptoms, opioid dependence, and risky substance use, but not pain. Conclusions Black individuals with chronic MSK pain who co-use opioids and cannabis warrant targeted interventions that address their needs. Tailored interventions could help address disparities in pain-related outcomes and opioid morbidity and mortality rates.


Subject(s)
Analgesics, Opioid , Black or African American , Chronic Pain , Opioid-Related Disorders , Humans , Female , Chronic Pain/drug therapy , Chronic Pain/ethnology , Adult , Male , Analgesics, Opioid/administration & dosage , Analgesics, Opioid/adverse effects , Black or African American/statistics & numerical data , Black or African American/psychology , Opioid-Related Disorders/ethnology , Opioid-Related Disorders/epidemiology , Middle Aged , Musculoskeletal Pain/ethnology , Musculoskeletal Pain/epidemiology , Substance-Related Disorders/epidemiology , Substance-Related Disorders/ethnology , Depression/epidemiology , Depression/ethnology
2.
J Addict Med ; 18(3): 335-338, 2024.
Article in English | MEDLINE | ID: mdl-38833558

ABSTRACT

OBJECTIVES: Overdose mortality has risen most rapidly among racial and ethnic minority groups while buprenorphine prescribing has increased disproportionately in predominantly non-Hispanic White urban areas. To identify whether buprenorphine availability equitably meets the needs of diverse populations, we examined the differential geographic availability of buprenorphine in areas with greater concentrations of racial and ethnic minority groups. METHODS: Using IQVIA longitudinal prescription data, IQVIA OneKey data, and Microsoft Bing Maps, we calculated 2 outcome measures across the continental United States: the number of buprenorphine prescribers per 1000 residents within a 30-minute drive of a ZIP code, and the number of buprenorphine prescriptions dispensed per capita at retail pharmacies among nearby buprenorphine prescribers. We then estimated differences in these outcomes by ZIP codes' racial and ethnic minority composition and rurality with t tests. RESULTS: Buprenorphine prescribers per 1000 residents within a 30-minute drive decreased by 3.8 prescribers per 1000 residents in urban ZIP codes (95% confidence interval = -4.9 to -2.7) and 2.6 in rural ZIP codes (95% confidence interval = -3.0 to -2.2) whose populations consisted of ≥5% racial and ethnic minority groups. There were 45% to 55% fewer prescribers in urban areas and 62% to 79% fewer prescribers in rural areas as minority composition increased. Differences in dispensed buprenorphine per capita were similar but larger in magnitude. CONCLUSIONS: Achieving more equitable buprenorphine access requires not only increasing the number of buprenorphine-prescribing clinicians; in urban areas with higher racial and ethnic minority group populations, it also requires efforts to promote greater buprenorphine prescribing among already prescribing clinicians.


Subject(s)
Buprenorphine , Healthcare Disparities , Buprenorphine/therapeutic use , Humans , United States , Healthcare Disparities/statistics & numerical data , Healthcare Disparities/ethnology , Health Services Accessibility/statistics & numerical data , Narcotic Antagonists/therapeutic use , Urban Population/statistics & numerical data , Rural Population/statistics & numerical data , Opiate Substitution Treatment/statistics & numerical data , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/ethnology , Ethnic and Racial Minorities/statistics & numerical data , Ethnicity/statistics & numerical data
3.
Ann Epidemiol ; 94: 81-90, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38710239

ABSTRACT

PURPOSE: Identifying predictors of opioid overdose following release from prison is critical for opioid overdose prevention. METHODS: We leveraged an individually linked, state-wide database from 2015-2020 to predict the risk of opioid overdose within 90 days of release from Massachusetts state prisons. We developed two decision tree modeling schemes: a model fit on all individuals with a single weight for those that experienced an opioid overdose and models stratified by race/ethnicity. We compared the performance of each model using several performance measures and identified factors that were most predictive of opioid overdose within racial/ethnic groups and across models. RESULTS: We found that out of 44,246 prison releases in Massachusetts between 2015-2020, 2237 (5.1%) resulted in opioid overdose in the 90 days following release. The performance of the two predictive models varied. The single weight model had high sensitivity (79%) and low specificity (56%) for predicting opioid overdose and was more sensitive for White non-Hispanic individuals (sensitivity = 84%) than for racial/ethnic minority individuals. CONCLUSIONS: Stratified models had better balanced performance metrics for both White non-Hispanic and racial/ethnic minority groups and identified different predictors of overdose between racial/ethnic groups. Across racial/ethnic groups and models, involuntary commitment (involuntary treatment for alcohol/substance use disorder) was an important predictor of opioid overdose.


Subject(s)
Decision Trees , Opiate Overdose , Humans , Male , Opiate Overdose/epidemiology , Adult , Female , Massachusetts/epidemiology , Opioid-Related Disorders/epidemiology , Opioid-Related Disorders/ethnology , Prisoners/statistics & numerical data , Prisons/statistics & numerical data , Middle Aged , Analgesics, Opioid/poisoning , Analgesics, Opioid/adverse effects , Ethnicity/statistics & numerical data , Young Adult
4.
J Subst Use Addict Treat ; 161: 209338, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38537872

ABSTRACT

BACKGROUND: Little is known about representation in trials aimed at addressing Opioid Use Disorder. This is a crucial issue given high mortality rates overall and substantial differences in death rates across racial/ethnic groups. METHODS: We analyzed data from clinical trials, data on Census population, data on new admissions to treatment facilities with a diagnosis of Opioid Use Disorder, and mortality data. RESULTS: We found that Native American people (who face the highest opioid-related mortality burden in the United States) were under-represented in clinical trials. Black people (who face the second highest mortality rate) were enrolled at levels that exceeded those expected. Our results suggest the need for increased efforts to include Native Americans in OUD clinical trials and also that researchers should consider the possibility that high levels of enrollment among black Americans may represent an undue burden. We found ambiguous results for Asian American and Hispanic people. Our analysis also suggests that White people were represented at levels below those expected, although they were a majority of clinical trials participants. CONCLUSION: Overall, these findings highlight the importance of equity in clinical trials and major gaps in terms of representation.


Subject(s)
Clinical Trials as Topic , Opioid-Related Disorders , Humans , Opioid-Related Disorders/ethnology , Opioid-Related Disorders/epidemiology , Opioid-Related Disorders/mortality , United States/epidemiology , Ethnicity/statistics & numerical data , Hispanic or Latino/statistics & numerical data , Male , Patient Selection , White People/statistics & numerical data , Black or African American/statistics & numerical data , Female
5.
Health Educ Behav ; 51(3): 416-424, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38281101

ABSTRACT

The rise in opioid misuse coincides with increased sexually transmitted infection (STI) and HIV incidence. Transactional sex is an under-researched phenomenon among Black Americans who misuse opioids, and may increase their risk of STI or HIV transmission. Given the disproportionate impact of the opioid epidemic on Black Americans and the risks associated with opioid misuse, the current study aims to investigate sociostructural factors, history of violence, and sexual risk factors associated with transactional sex among Black men and women. A sample of n = 375 Black adult Kentuckians reporting opioid misuse completed a survey including transactional sex, sociostructural, violence history, and sexual risk measures. Results of chi-squares and independent samples t-tests revealed that compared to men who did not report engaging in transactional sex, men who engaged in transactional sex were less educated, reported being sexually assaulted or having an unwanted sexual experience in their lifetime, and were more likely to use opioids or cocaine before or during sex in the last year. Women who engaged in transactional sex had a history of violence, more structural barriers, higher psychological distress, and engaged in more sexual risk behaviors compared to women who did not engage in transactional sex. Implications for future research and interventions with this population are discussed.


Subject(s)
Black or African American , Opioid-Related Disorders , Sexual Behavior , Humans , Male , Female , Adult , Black or African American/statistics & numerical data , Black or African American/psychology , Opioid-Related Disorders/epidemiology , Opioid-Related Disorders/ethnology , Sexually Transmitted Diseases/epidemiology , Sexually Transmitted Diseases/ethnology , Sex Work/statistics & numerical data , Risk-Taking , Risk Factors , Surveys and Questionnaires , Middle Aged , HIV Infections/epidemiology , HIV Infections/ethnology
6.
Am J Health Promot ; 38(2): 205-218, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37955409

ABSTRACT

PURPOSE: To develop a culturally-tailored American Indian/Alaska Native (AI/AN) women's Facebook group supporting opioid recovery as an adjunct to medication. DESIGN: Community-based, qualitative approach. SETTING: Minnesota, U.S. PARTICIPANTS: AI/AN women in opioid recovery, interested parties, and a Community Advisory Committee (CAC) of AI/AN women with lived experience, health care providers, and community members. INTERVENTION: We developed evidence-based content focusing on stress/trauma and substance use, mindfulness, responding to triggers, and supportive community resources. Additional content centered on AI/AN culture was also selected. METHOD: Interviews were conducted by two women, then transcribed and coded using content analysis with NVivo software. Results were presented to CAC for further content refinement. RESULTS: CAC members (n = 10) guided study methods, intervention development, and dissemination activities. 14 AI/AN women (mean age 36.4 years; mean 6.7 months opioid abstinence) and 12 interested parties (7 men, 5 women) were receptive to an AI/AN gender-specific Facebook group, preferring content with AI/AN people and/or text resonating with AI/AN culture (e.g., Native traditions, family, personal stories, historical trauma). Recommendations included (1) protect confidentiality, (2) retain positivity, (3) incorporate resources and exercises to build coping skills, and (4) moderators should be authentic and relatable to build trust. CONCLUSIONS: Our approach provides a model for developing culturally tailored, appealing and effective social media interventions to support AI/AN women in recovery from opioid use disorder.


Subject(s)
American Indian or Alaska Native , Opioid-Related Disorders , Social Media , Adult , Female , Humans , Male , Advisory Committees , Alaska Natives , Analgesics, Opioid , Opioid-Related Disorders/ethnology , Opioid-Related Disorders/rehabilitation , Opioid-Related Disorders/therapy , Qualitative Research
7.
J Addict Med ; 17(4): 463-467, 2023.
Article in English | MEDLINE | ID: mdl-37579110

ABSTRACT

OBJECTIVE: We sought to identify the sociodemographic and clinical characteristics associated with homelessnesss, and explore the relationship between homelessnesss and treatment outcomes among Black individuals. METHODS: This is a secondary analysis of the subgroup of Black participants (n = 73) enrolled in "X:BOT," a 24-week multisite randomized clinical trial comparing the effectiveness of extended-release naltrexone versus sublingual buprenorphine-naloxone (n = 570). Outcomes included medication initiation, return to extramedical use of opioids assessed by both self-report and urine toxicology, and engagement in medications for opioid use disorder (MOUD) treatment at 28 weeks postrandomization. Descriptive statistics were performed. RESULTS: Black participants were mostly unmarried and male, and about a third were aged 21-30 years. Among people experiencing homelessnesss, more were uninsured (45.5% [10/22] vs 19.6% [10/51]), unemployed (77.3% [17/22] vs 64.7% [33/51]), and reported alcohol (40.9% [9/22] vs 23.5% [12/51]) and sedative use (54.5% [12/22] vs 17.6% [9/51]) within the previous 30 days. Compared with housed Black individuals, a slightly higher proportion of Black individuals experiencing homelessnesss successfully initiated study medication (81.1% [18/22] vs 72.6% [37/51]); similar proportions returned to opioid use during the trial (68.2% [15/22] vs 68.6% [35/51]) and were engaged in MOUD at 28 weeks after trial entry (72.2% [13/18] vs 69.7% [23/33]) among participants located for follow-up. CONCLUSIONS: These descriptive results among Black patients participating in a trial of MOUD suggest that efficacious MOUD is possible despite homelessnesss with additional clinical supports such as those provided by a clinical trial.


Subject(s)
Black or African American , Ill-Housed Persons , Opioid-Related Disorders , Adult , Humans , Male , Analgesics, Opioid/adverse effects , Buprenorphine, Naloxone Drug Combination/therapeutic use , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/ethnology , Treatment Outcome , Female , Young Adult
8.
JAMA Netw Open ; 6(8): e2328627, 2023 08 01.
Article in English | MEDLINE | ID: mdl-37566414

ABSTRACT

Importance: Medication for opioid use disorder (MOUD) (eg, buprenorphine and naltrexone) can be offered in primary care, but barriers to implementation exist. Objective: To evaluate an implementation intervention over 2 years to explore experiences and perspectives of multidisciplinary primary care (PC) teams initiating or expanding MOUD. Design, Setting, and Participants: This survey-based and ethnographic qualitative study was conducted at 12 geographically and structurally diverse primary care clinics that enrolled in a hybrid effectiveness-implementation study from July 2020 to July 2022 and included PC teams (prescribing clinicians, nonprescribing behavioral health care managers, and consulting psychiatrists). Survey data analysis was conducted from February to April 2022. Exposure: Implementation intervention (external practice facilitation) to integrate OUD treatment alongside existing collaborative care for mental health services. Measures: Data included (1) quantitative surveys of primary care teams that were analyzed descriptively and triangulated with qualitative results and (2) qualitative field notes from ethnographic observation of clinic implementation meetings analyzed using rapid assessment methods. Results: Sixty-two primary care team members completed the survey (41 female individuals [66%]; 1 [2%] American Indian or Alaskan Native, 4 [7%] Asian, 5 [8%] Black or African American, 5 [8%] Hispanic or Latino, 1 [2%] Native Hawaiian or Other Pacific Islander, and 46 [4%] White individuals), of whom 37 (60%) were between age 25 and 44 years. An analysis of implementation meetings (n = 362) and survey data identified 4 themes describing multilevel factors associated with PC team provision of MOUD during implementation, with variation in their experience across clinics. Themes characterized challenges with clinical administrative logistics that limited the capacity to provide rapid access to care and patient engagement as well as clinician confidence to discuss aspects of MOUD care with patients. These challenges were associated with conflicting attitudes among PC teams toward expanding MOUD care. Conclusions and Relevance: The results of this survey and qualitative study of PC team perspectives suggest that PC teams need flexibility in appointment scheduling and the capacity to effectively engage patients with OUD as well as ongoing training to maintain clinician confidence in the face of evolving opioid-related clinical issues. Future work should address structural challenges associated with workload burden and limited schedule flexibility that hinder MOUD expansion in PC settings.


Subject(s)
Opioid-Related Disorders , Primary Health Care , Adult , Female , Humans , Ambulatory Care Facilities/organization & administration , Ambulatory Care Facilities/statistics & numerical data , American Indian or Alaska Native/statistics & numerical data , Analgesics, Opioid/therapeutic use , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/epidemiology , Opioid-Related Disorders/ethnology , Primary Health Care/methods , Primary Health Care/organization & administration , Primary Health Care/statistics & numerical data , Male , Patient Care Team/statistics & numerical data , Asian/statistics & numerical data , Black or African American/statistics & numerical data , Hispanic or Latino/statistics & numerical data , Native Hawaiian or Other Pacific Islander/statistics & numerical data , White/statistics & numerical data , Appointments and Schedules , Workload
9.
MMWR Surveill Summ ; 72(3): 1-14, 2023 05 05.
Article in English | MEDLINE | ID: mdl-37130060

ABSTRACT

Problem: Medication for opioid use disorder (MOUD) is recommended for persons with opioid use disorder (OUD) during pregnancy. However, knowledge gaps exist about best practices for management of OUD during pregnancy and these data are needed to guide clinical care. Period Covered: 2014-2021. Description of the System: Established in 2019, the Maternal and Infant Network to Understand Outcomes Associated with Medication for Opioid Use Disorder During Pregnancy (MAT-LINK) is a surveillance network of seven clinical sites in the United States. Boston Medical Center, Kaiser Permanente Northwest, The Ohio State University, and the University of Utah were the initial clinical sites in 2019. In 2021, three clinical sites were added to the network (the University of New Mexico, the University of Rochester, and the University of South Florida). Persons receiving care at the seven clinical sites are diverse in terms of geography, urbanicity, race and ethnicity, insurance coverage, and type of MOUD received. The goal of MAT-LINK is to capture demographic and clinical information about persons with OUD during pregnancy to better understand the effect of MOUD on outcomes and, ultimately, provide information for clinical care and public health interventions for this population. MAT-LINK maintains strict confidentiality through robust information technology architecture. MAT-LINK surveillance methods, population characteristics, and evaluation findings are described in this inaugural surveillance report. This report is the first to describe the system, presenting detailed information on funding, structure, data elements, and methods as well as findings from a surveillance evaluation. The findings presented in this report are limited to selected demographic characteristics of pregnant persons overall and by MOUD treatment status. Clinical and outcome data are not included because data collection and cleaning have not been completed; initial analyses of clinical and outcome data will begin in 2023. Results: The MAT-LINK surveillance network gathered data on 5,541 reported pregnancies with a known pregnancy outcome during 2014-2021 among persons with OUD from seven clinical sites. The mean maternal age was 29.7 (SD = ±5.1) years. By race and ethnicity, 86.3% of pregnant persons were identified as White, 25.4% as Hispanic or Latino, and 5.8% as Black or African American. Among pregnant persons, 81.6% had public insurance, and 84.4% lived in urban areas. Compared with persons not receiving MOUD during pregnancy, those receiving MOUD during pregnancy were more likely to be older and White and to have public insurance. The evaluation of the surveillance system found that the initial four clinical sites were not representative of demographics of the South or Southwest regions of the United States and had low representation from certain racial and ethnic groups compared with the overall U.S. population; however, the addition of three clinical sites in 2021 made the surveillance network more representative. Automated extraction and processing improved the speed of data collection and analysis. The ability to add new clinical sites and variables demonstrated the flexibility of MAT-LINK. Interpretation: MAT-LINK is the first surveillance system to collect comprehensive, longitudinal data on pregnant person-infant dyads with perinatal outcomes associated with MOUD during pregnancy from multiple clinical sites. Analyses of clinical site data demonstrated different sociodemographic characteristics between the MOUD and non-MOUD treatment groups. Public Health Actions: MAT-LINK is a timely and flexible surveillance system with data on approximately 5,500 pregnancies. Ongoing data collection and analyses of these data will provide information to support clinical and public health guidance to improve health outcomes among pregnant persons with OUD and their children.


Subject(s)
Opioid-Related Disorders , Population Surveillance , Adult , Female , Humans , Infant , Pregnancy , Ethnicity/statistics & numerical data , Family , Hispanic or Latino/statistics & numerical data , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/epidemiology , Opioid-Related Disorders/ethnology , Population Surveillance/methods , United States/epidemiology , Pregnancy Outcome , Young Adult , Black or African American/statistics & numerical data , White/statistics & numerical data
10.
N Engl J Med ; 388(19): 1779-1789, 2023 May 11.
Article in English | MEDLINE | ID: mdl-37163624

ABSTRACT

BACKGROUND: Since 2010, Black persons in the United States have had a greater increase in opioid overdose-related mortality than other groups, but national-level evidence characterizing racial and ethnic disparities in the use of medications for opioid use disorder (OUD) is limited. METHODS: We used Medicare claims data from the 2016-2019 period for a random 40% sample of fee-for-service beneficiaries who were Black, Hispanic, or White; were eligible for Medicare owing to disability; and had an index event related to OUD (nonfatal overdose treated in an emergency department or inpatient setting, hospitalization with injection drug use-related infection, or inpatient or residential rehabilitation or detoxification care). We measured the receipt of medications to treat OUD (buprenorphine, naltrexone, and naloxone), the receipt of high-risk medications (opioid analgesics and benzodiazepines), and health care utilization, all in the 180 days after the index event. We estimated differences in outcomes according to race and ethnic group with adjustment for beneficiary age, sex, index event, count of chronic coexisting conditions, and state of residence. RESULTS: We identified 25,904 OUD-related index events among 23,370 beneficiaries, with 3937 events (15.2%) occurring among Black patients, 2105 (8.1%) among Hispanic patients, and 19,862 (76.7%) among White patients. In the 180 days after the index event, patients received buprenorphine after 12.7% of events among Black patients, after 18.7% of those among Hispanic patients, and after 23.3% of those among White patients; patients received naloxone after 14.4%, 20.7%, and 22.9%, respectively; and patients received benzodiazepines after 23.4%, 29.6%, and 37.1%, respectively. Racial differences in the receipt of medications to treat OUD did not change appreciably from 2016 to 2019 (buprenorphine receipt: after 9.1% of index events among Black patients vs. 21.6% of those among White patients in 2016, and after 14.1% vs. 25.5% in 2019). In all study groups, patients had multiple ambulatory visits in the 180 days after the index event (mean number of visits, 6.6 after events among Black patients, 6.7 after events among Hispanic patients, and 7.6 after events among White patients). CONCLUSIONS: Racial and ethnic differences in the receipt of medications to treat OUD after an index event related to this disorder among patients with disability were substantial and did not change over time. The high incidence of ambulatory visits in all groups showed that disparities persisted despite frequent health care contact. (Funded by the National Institute on Drug Abuse and the National Institute on Aging.).


Subject(s)
Analgesics, Opioid , Benzodiazepines , Healthcare Disparities , Narcotic Antagonists , Opioid-Related Disorders , Aged , Humans , Analgesics, Opioid/administration & dosage , Analgesics, Opioid/therapeutic use , Benzodiazepines/administration & dosage , Benzodiazepines/therapeutic use , Buprenorphine/therapeutic use , Medicare/statistics & numerical data , Naloxone/therapeutic use , Opioid-Related Disorders/complications , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/epidemiology , Opioid-Related Disorders/ethnology , United States/epidemiology , Healthcare Disparities/ethnology , Healthcare Disparities/statistics & numerical data , Opiate Overdose/epidemiology , Opiate Overdose/ethnology , Opiate Overdose/etiology , Opiate Overdose/prevention & control , Black or African American/statistics & numerical data , White/statistics & numerical data , Hispanic or Latino/statistics & numerical data , Naltrexone/therapeutic use , Narcotic Antagonists/administration & dosage , Narcotic Antagonists/therapeutic use
11.
Addiction ; 118(8): 1540-1548, 2023 08.
Article in English | MEDLINE | ID: mdl-36905290

ABSTRACT

BACKGROUND AND AIMS: The Opioid Use Disorder (OUD) Cascade of Care is a public health model that has been used to measure population-level OUD risk, treatment engagement, retention, service and outcome indicators. However, no studies have examined its relevance for American Indian and Alaska Native (AI/AN) communities. Thus, we aimed to understand (1) the utility of existing stages and (2) the relative 'fit' of the OUD Cascade of Care from a tribal perspective. DESIGN, SETTING, PARTICIPANTS AND MEASUREMENTS: Qualitative analysis of in-depth interviews with 20 individuals who were knowledgeable regarding the treatment of OUD in an Anishinaabe tribal setting in Minnesota, USA. Community member roles included clinicians, peer support specialists and cultural practitioners, among others. Thematic analysis was used to analyze the data. FINDINGS: Participants identified the key transition points of prevention, assessment, inpatient/outpatient pathways and recovery as relevant to their community. They re-imagined an Aanji'bide (Changing our Paths) model of opioid recovery and change that was non-linear; included developmental stage and individual pathways; and demonstrated resilience through connection to culture/spirituality, community and others. CONCLUSIONS: Community members living/working in a rural tribal nation in Minnesota, USA identified non-linearity and cultural connection as key elements to include in an Anishinaabe-centered model of opioid recovery and change.


Subject(s)
Culturally Competent Care , Indians, North American , Opioid-Related Disorders , Patient-Centered Care , Humans , Minnesota , Opioid-Related Disorders/diagnosis , Opioid-Related Disorders/ethnology , Opioid-Related Disorders/therapy , United States , Culturally Competent Care/ethnology , Culturally Competent Care/methods , Rural Population , Patient-Centered Care/methods
12.
Addict Biol ; 27(1): e13099, 2022 01.
Article in English | MEDLINE | ID: mdl-34611967

ABSTRACT

Polygenic risk scores (PRS) represent an individual's summed genetic risk for a trait and can serve as biomarkers for disease. Less is known about the utility of PRS as a means to quantify genetic risk for substance use disorders (SUDs) than for many other traits. Nonetheless, the growth of large, electronic health record-based biobanks makes it possible to evaluate the association of SUD PRS with other traits. We calculated PRS for smoking initiation, alcohol use disorder (AUD), and opioid use disorder (OUD) using summary statistics from the Million Veteran Program sample. We then tested the association of each PRS with its primary phenotype in the Penn Medicine BioBank (PMBB) using all available genotyped participants of African or European ancestry (AFR and EUR, respectively) (N = 18,612). Finally, we conducted phenome-wide association analyses (PheWAS) separately by ancestry and sex to test for associations across disease categories. Tobacco use disorder was the most common SUD in the PMBB, followed by AUD and OUD, consistent with the population prevalence of these disorders. All PRS were associated with their primary phenotype in both ancestry groups. PheWAS results yielded cross-trait associations across multiple domains, including psychiatric disorders and medical conditions. SUD PRS were associated with their primary phenotypes; however, they are not yet predictive enough to be useful diagnostically. The cross-trait associations of the SUD PRS are indicative of a broader genetic liability. Future work should extend findings to additional population groups and for other substances of abuse.


Subject(s)
Comorbidity , Electronic Health Records/statistics & numerical data , Genetic Predisposition to Disease/genetics , Substance-Related Disorders/ethnology , Substance-Related Disorders/genetics , Adult , Aged , Aged, 80 and over , Alcoholism/ethnology , Alcoholism/genetics , Black People/genetics , Female , Genome-Wide Association Study , Genotype , Humans , Male , Middle Aged , Multifactorial Inheritance , Opioid-Related Disorders/ethnology , Opioid-Related Disorders/genetics , Phenotype , Risk Factors , Sex Factors , Tobacco Use Disorder/ethnology , Tobacco Use Disorder/genetics , White People/genetics
13.
JAMA Netw Open ; 4(7): e2118801, 2021 07 01.
Article in English | MEDLINE | ID: mdl-34323984

ABSTRACT

Importance: Although racial disparities in acute pain control are well established, the role of patient analgesic preference and the factors associated with these disparities remain unclear. Objective: To characterize racial disparities in opioid prescribing for acute pain after accounting for patient preference and to test the hypothesis that racial disparities may be mitigated by giving clinicians additional information about their patients' treatment preferences and risk of opioid misuse. Design, Setting, and Participants: This study is a secondary analysis of data collected from Life STORRIED (Life Stories for Opioid Risk Reduction in the ED), a multicenter randomized clinical trial conducted between June 2017 and August 2019 in the emergency departments (EDs) of 4 academic medical centers. Participants included 1302 patients aged 18 to 70 years who presented to the ED with ureter colic or musculoskeletal back and/or neck pain. Interventions: The treatment arm was randomized to receive a patient-facing intervention (not examined in this secondary analysis) and a clinician-facing intervention that consisted of a form containing information about each patient's analgesic treatment preference and risk of opioid misuse. Main Outcomes and Measures: Concordance between patient preference for opioid-containing treatment (assessed before ED discharge) and receipt of an opioid prescription at ED discharge. Results: Among 1302 participants in the Life STORRIED clinical trial, 1012 patients had complete demographic and treatment preference data available and were included in this secondary analysis. Of those, 563 patients (55.6%) self-identified as female, with a mean (SD) age of 40.8 (14.1) years. A total of 455 patients (45.0%) identified as White, 384 patients (37.9%) identified as Black, and 173 patients (17.1%) identified as other races. After controlling for demographic characteristics and clinical features, Black patients had lower odds than White patients of receiving a prescription for opioid medication at ED discharge (odds ratio [OR], 0.42; 95% CI, 0.27-0.65). When patients who did and did not prefer opioids were considered separately, Black patients continued to have lower odds of being discharged with a prescription for opioids compared with White patients (among those who preferred opioids: OR, 0.43 [95% CI, 0.24-0.77]; among those who did not prefer opioids: OR, 0.45 [95% CI, 0.23-0.89]). These disparities were not eliminated in the treatment arm, in which clinicians were given additional data about their patients' treatment preferences and risk of opioid misuse. Conclusions and Relevance: In this secondary analysis of data from a randomized clinical trial, Black patients received different acute pain management than White patients after patient preference was accounted for. These disparities remained after clinicians were given additional patient-level data, suggesting that a lack of patient information may not be associated with opioid prescribing disparities. Trial Registration: ClinicalTrials.gov Identifier: NCT03134092.


Subject(s)
Acute Pain/psychology , Analgesics, Opioid/therapeutic use , Healthcare Disparities/ethnology , Patient Preference/ethnology , Risk Assessment/ethnology , Academic Medical Centers , Acute Pain/drug therapy , Acute Pain/ethnology , Adult , Black People/psychology , Emergency Service, Hospital , Female , Humans , Male , Middle Aged , Odds Ratio , Opioid-Related Disorders/ethnology , Opioid-Related Disorders/prevention & control , Pain Management/psychology , Pain Management/statistics & numerical data , Patient Discharge/statistics & numerical data , Patient Preference/statistics & numerical data , Practice Patterns, Physicians'/statistics & numerical data , Prescriptions/statistics & numerical data , Randomized Controlled Trials as Topic , Risk Assessment/statistics & numerical data , White People/psychology
14.
Anthropol Med ; 28(2): 223-238, 2021 Jun.
Article in English | MEDLINE | ID: mdl-34058932

ABSTRACT

Opioids, a set of potent pain medications, have numerous known deleterious side effects, ranging from constipation to respiratory depression and death, and yet they are routinely prescribed and administered in biomedical settings. Situated against the backdrop of the US opioid epidemic, this paper examines how the iatrogenic and inadvertent harms and complications caused by opioid administration in clinical settings are experienced by clinicians as forms of moral injury. 'Moral injury' describes a moral agent's experience of perpetrating or being unable to prevent events that are at odds with their moral beliefs and social expectations. This concept powerfully extends Illich's notion of clinical iatrogenesis, which refers to harms experienced by patients; instead, 'moral injury' indexes forms of harm that extend beyond patients to those providing them care. Using an analytic auto-ethnographic approach based on more than a decade of clinical practice in urban hospitals in the Midwestern and Northeastern United States, the authors describe interactions with patients on opioids whose treatment trajectories are fraught with iatrogenic complications, and explore how biomedical institutions and systems further harm vulnerable patients who receive and are addicted to opioids. Though anxious to avoid harming their patients, clinicians are disempowered by hierarchical systems of medical decision-making, which hinder their ability to always act in what they feel are the patient's best interests. This paper highlights the emotional/affective distress and ambivalence experienced by physicians when making decisions about whether to administer or prescribe opioids. Ultimately, the paper demonstrates how iatrogenesis and moral injury are concomitantly produced through cascades of decision-making and local health systems, rather than individual clinical decisions alone.


Subject(s)
Analgesics, Opioid , Iatrogenic Disease/ethnology , Opioid Epidemic , Opioid-Related Disorders/ethnology , Aged , Analgesics, Opioid/adverse effects , Analgesics, Opioid/therapeutic use , Anthropology, Medical , Clinical Decision-Making , Humans , Male , Middle Aged , Physician-Patient Relations , United States/ethnology
15.
Anthropol Med ; 28(2): 239-254, 2021 Jun.
Article in English | MEDLINE | ID: mdl-34190020

ABSTRACT

This paper explores how poor health outcomes in the HIV/AIDS and opioid epidemics in the United States are undergirded by iatrogenesis. Data are drawn from two projects in Southern California: one among men who have sex with men (MSM) engaging with pre-exposure prophylaxis to HIV (PrEP) and the other in a public hospital system encountering patients with chronic pain and opioid use disorder (OUD). Ethnographic evidence demonstrates how efforts to minimize risk via PrEP and opioid prescription regulation paradoxically generate new forms of risk. Biomedical risk management paradigms engaged across the paper's two ethnographic field sites hinge on the production and governance of deserving patienthood, which is defined by providers and experienced by patients through moral judgments about risk underlying both increased surveillance and abandonment. This paper argues that the logic of deservingness disconnects clinical evaluations of risk from patients' lived, intersectional experiences of race, class, gender, and sexuality. This paper's analysis thus re-locates patients in the context of broader historical and sociopolitical trajectories to highlight how notions of clinical risk designed to protect patients can in fact imperil them. Misalignment between official, clinical constructions of risk and the embodied experience of risk borne by patients produces iatrogenesis.


Subject(s)
Attitude of Health Personnel/ethnology , HIV Infections , Iatrogenic Disease/ethnology , Opioid Epidemic , Opioid-Related Disorders , Anthropology, Medical , Anti-HIV Agents/therapeutic use , Female , HIV Infections/drug therapy , HIV Infections/ethnology , Homosexuality, Male , Humans , Male , Middle Aged , Opioid-Related Disorders/ethnology , Opioid-Related Disorders/therapy , Pre-Exposure Prophylaxis , Risk Management , United States
16.
Am J Public Health ; 111(5): 896-906, 2021 05.
Article in English | MEDLINE | ID: mdl-33734839

ABSTRACT

Failed by mainstream medical institutions, 1970s revolutionaries of color sought to take health care into their own hands. A lesser-known phenomenon was their use of acupuncture. In 1970, an alliance of Black, Latinx, and White members at Lincoln Detox, a drug treatment program in the South Bronx area of New York City, learned of acupuncture as an alternative to methadone. In Oakland, California, Tolbert Small, MD, used acupuncture for pain management following his exposure to the practice as part of a 1972 Black Panther Party delegation to China. Unaware of one another then, the Lincoln team and Small were similarly driven to "serve the people, body and soul." They enacted "toolkit care,"-self-assembled, essential community care-in response to dire situations such as the intensifying drug crisis. These stories challenge the traditional American history of acupuncture and contribute innovations to and far beyond the addiction field by presenting a holistic model of prevention and care. They advance a nuanced definition of integrative medicine as one that combines medical and social practices, and their legacies are currently carried out by thousands of health care practitioners globally.


Subject(s)
Acupuncture Therapy/methods , Opioid-Related Disorders/ethnology , Opioid-Related Disorders/therapy , Humans , Minority Groups , New York City/epidemiology , Socioeconomic Factors
17.
Harv Rev Psychiatry ; 29(2): 108-130, 2021.
Article in English | MEDLINE | ID: mdl-33666395

ABSTRACT

BACKGROUND: There are multiple aspects of the opioid crisis among Black people, who have been left out of the broader conversation. Despite evidence of increased opioid overdose deaths, less is known about opioid use among Black people. This review synthesizes research on Black people who use opioids; the goals are to advance knowledge, highlight research gaps, and inform clinical practice. METHODS: This rapid review investigating opioid use among Black people utilized systematic review methods and was conducted according to a predefined protocol with clear inclusion criteria (PROSPERO ID: 177071). A comprehensive search strategy was used, including published and gray-literature sources (i.e., literature that has not been formally published). A narrative summary of the results is presented. RESULTS: A total of 76 works were selected for inclusion and full text review. Sex, age, geographic location, and involvement in the carceral system were associated with the use of opioids among Black individuals. Non-epidemiologic factors included treatment-seeking patterns, disparate clinician prescribing, and social determinants. CONCLUSIONS: Through this rapid review we suggest three main areas of focus: (1) including culturally informed collection methods in epidemiologic surveys to accurately reflect prevalences, (2) funding research that specifically addresses the importance of culture in accessing treatment, and (3) directly studying how social determinants can improve or exacerbate health outcomes. Focusing on the unique needs of Black people who use opioids is warranted to increase treatment initiation and adherence among a population less likely to engage with the traditional health care system.


Subject(s)
Analgesics, Opioid , Black People , Opioid-Related Disorders , Cultural Characteristics , Humans , Opioid-Related Disorders/ethnology
18.
Med Anthropol Q ; 35(2): 159-189, 2021 06.
Article in English | MEDLINE | ID: mdl-33715229

ABSTRACT

Opioid abuse is an increasingly global phenomenon. Rather than assuming it to be a uniformly global or neoliberal pathology, how might we better understand comparative and locally specific dimensions of opioid addiction? Working with neighborhoods as a unit of analysis, this article analyzes the striking differences between patterns of addiction and violence in two proximate and seemingly similar urban poor neighborhoods in Delhi, India. Rather than global or national etiologies, I suggest that an attention to sharp ecological variation within epidemics challenges social scientists to offer more fine-grained diagnostics. Using a combination of quantitative and ethnographic methods, I show how heroin addiction and collective violence might be understood as expressions of what Durkheim called "suicido-genetic currents." I suggest the idea of varying currents as an alternative to the sociology of neighborhood "effects" in understanding significant differences in patterns of self-harm and injury across demographically similar localities.


Subject(s)
Opioid-Related Disorders , Residence Characteristics , Violence/ethnology , Adult , Anthropology, Medical , Female , HIV Infections , Humans , India/ethnology , Male , Opioid-Related Disorders/ethnology , Opioid-Related Disorders/mortality , Urban Population
19.
Med Care ; 59(5): 393-401, 2021 05 01.
Article in English | MEDLINE | ID: mdl-33734194

ABSTRACT

AIM: The aim of this study was to characterize quality of buprenorphine care for opioid use disorder (OUD) by quantifying buprenorphine initiation, engagement, and maintenance for individuals in a large, diverse, real-world cohort in the United States. DESIGN: This was a retrospective cohort analysis. SETTING: OUD treatment in the outpatient setting. PARTICIPANTS: A total of 45,210 commercially insured and Medicare Advantage (MA) enrollees 18 years or older in the OptumLabs Data Warehouse with an index diagnosis of OUD between January 1, 2018 and December 31, 2018. INTERVENTIONS: Treatment with buprenorphine. MEASUREMENTS: We calculated 6 measures of buprenorphine treatment quality. We conducted survival analyses to characterize treatment duration and logistic regressions to evaluate the association between clinical and sociodemographic characteristics and quality. FINDINGS: Of 45,210 eligible individuals with OUD, ∼1 in 10 (n=4600, 10.2%) initiated buprenorphine within 365 days following diagnosis (Measure #1) and 2850 individuals (6.3%) initiated buprenorphine within 14 days of diagnosis (Measure #2). Of individuals initiating treatment within 14 days of diagnosis, 1769 (62.1%) had 2 or more buprenorphine claims within 34 days of initiation (Measure #3). Of the 4600 individuals who received buprenorphine, 2300 (50.0%) were maintained in care with 180 days or more of covered buprenorphine treatment during 365 days after diagnosis (Measure #4). Finally, of the 4600 individuals who received buprenorphine, 2543 (55.3%) did not fill any other concurrent opioid analgesic (Measure #5) and 2951 (64.2%) did not fill any concurrent benzodiazepine (Measure #6). Quality was generally lower for individuals with MA compared with commercial coverage and among Hispanic and Black adults compared with White adults. CONCLUSION: Widespread gaps exist in quality of buprenorphine treatment initiation, engagement, and maintenance among commercially insured and MA enrollees with OUD.


Subject(s)
Analgesics, Opioid/therapeutic use , Buprenorphine/therapeutic use , Insurance, Health/statistics & numerical data , Medicare Part C/statistics & numerical data , Opioid-Related Disorders , Private Sector , Quality of Health Care , Adult , Aged , Female , Humans , Male , Middle Aged , Opiate Substitution Treatment , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/ethnology , Retrospective Studies , United States
20.
Drug Alcohol Depend ; 221: 108588, 2021 04 01.
Article in English | MEDLINE | ID: mdl-33639569

ABSTRACT

OBJECTIVE: To characterize racial/ethnic differences in past-year prescription opioid misuse and heroin use. METHODS: Data on 1,117,086 individuals age 12 and older were from the 1999-2018 National Survey on Drug Use and Health. We compared relative prevalences across 6 racial/ethnic groups for prescription opioid misuse analyses and 4 racial/ethnic groups for heroin analyses. Unadjusted and gender- and age-adjusted prevalences are reported for 5 time periods (1999-2002, 2003-2006, 2007-2010, 2011-2014, 2015-2018). Survey-weighted Poisson regression models with robust variance were used to estimate risk ratios by race/ethnicity and to test for time trends. RESULTS: Prescription opioid misuse was significantly higher among non-Hispanic White individuals than among Black, Hispanic, and Asian individuals across all time periods, yet was highest among Native American individuals in every time period. The relative difference between White and both Hispanic and Asian individuals significantly widened over time, whereas the gap between Black and White individuals significantly decreased. Early in the study period, heroin use was highest among Black and Hispanic individuals. Heroin use among White individuals first surpassed all other groups in 2007-2010 and continued to steadily increase, more than doubling from 1999-2002 to 2015-2018. CONCLUSIONS: While heroin use has risen among all racial/ethnic groups, the demographics of heroin use have changed significantly in the past two decades such that prevalence is now highest among White individuals. Opioid prevention and treatment initiatives should both be informed by the changing demographics of heroin use and seek to reduce opioid-related harms and expand treatment access equitably for all racial/ethnic groups.


Subject(s)
Heroin , Opioid-Related Disorders/epidemiology , Adult , Black or African American/statistics & numerical data , Analgesics, Opioid , Child , Ethnicity/statistics & numerical data , Female , Hispanic or Latino/statistics & numerical data , Humans , Male , Middle Aged , Opioid-Related Disorders/ethnology , Prevalence , Surveys and Questionnaires , United States/epidemiology , White People/statistics & numerical data
SELECTION OF CITATIONS
SEARCH DETAIL
...